Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations

v3.24.1
Consolidated Statements of Operations - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Operating expenses:    
Research and development expenses $ 11,112,257 $ 8,933,314
General and administrative expenses 9,070,124 6,143,527
Ratchet share expense   1,099,360
Total operating expenses 20,182,381 16,176,201
Loss from operations (20,182,381) (16,176,201)
Other income (expense):    
Interest expense (6,863) (6,967)
Interest income 34,490 1,870
Australian research and development incentives 176,719 313,625
Change in fair value of warrant liability 205,130 98,394
Other income (expense), net 409,476 406,922
Net loss (19,772,905) (15,769,279)
Deemed dividend on warrant modification   (450,578)
Net loss attributable to MAIA Biotechnology, Inc. shareholders $ (19,772,905) $ (16,219,857)
Net loss per share    
Net loss per share basic $ (1.49) $ (1.75)
Net loss per share diluted $ (1.49) $ (1.75)
Weighted average common shares outstanding basic 13,261,572 9,276,761
Weighted average common shares outstanding diluted 13,261,572 9,276,761